Logo image of ACRS

ACLARIS THERAPEUTICS INC (ACRS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACRS - US00461U1051 - Common Stock

2.92 USD
-0.09 (-2.99%)
Last: 12/5/2025, 8:01:59 PM
2.92 USD
0 (0%)
After Hours: 12/5/2025, 8:01:59 PM
Fundamental Rating

3

ACRS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. The financial health of ACRS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ACRS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACRS had negative earnings in the past year.
ACRS had a negative operating cash flow in the past year.
In the past 5 years ACRS always reported negative net income.
In the past 5 years ACRS always reported negative operating cash flow.
ACRS Yearly Net Income VS EBIT VS OCF VS FCFACRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ACRS has a Return On Assets of -80.71%. This is in the lower half of the industry: ACRS underperforms 72.92% of its industry peers.
The Return On Equity of ACRS (-117.97%) is worse than 65.10% of its industry peers.
Industry RankSector Rank
ROA -80.71%
ROE -117.97%
ROIC N/A
ROA(3y)-46.3%
ROA(5y)-49.43%
ROE(3y)-61.73%
ROE(5y)-73.31%
ROIC(3y)N/A
ROIC(5y)N/A
ACRS Yearly ROA, ROE, ROICACRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

With a Gross Margin value of 3.98%, ACRS perfoms like the industry average, outperforming 50.52% of the companies in the same industry.
In the last couple of years the Gross Margin of ACRS has grown nicely.
ACRS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.2%
GM growth 5Y35.7%
ACRS Yearly Profit, Operating, Gross MarginsACRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACRS has more shares outstanding
The number of shares outstanding for ACRS has been increased compared to 5 years ago.
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACRS Yearly Shares OutstandingACRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACRS Yearly Total Debt VS Total AssetsACRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -4.68, we must say that ACRS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.68, ACRS is not doing good in the industry: 60.42% of the companies in the same industry are doing better.
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.68
ROIC/WACCN/A
WACC9.14%
ACRS Yearly LT Debt VS Equity VS FCFACRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 3.92 indicates that ACRS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.92, ACRS is in line with its industry, outperforming 58.85% of the companies in the same industry.
ACRS has a Quick Ratio of 3.92. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ACRS (3.92) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.92
Quick Ratio 3.92
ACRS Yearly Current Assets VS Current LiabilitesACRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

ACRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -165.38%.
Looking at the last year, ACRS shows a very negative growth in Revenue. The Revenue has decreased by -41.87% in the last year.
The Revenue has been growing by 34.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-165.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-41.87%
Revenue growth 3Y40.43%
Revenue growth 5Y34.65%
Sales Q2Q%-24.09%

3.2 Future

ACRS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.25% yearly.
The Revenue is expected to grow by 24.44% on average over the next years. This is a very strong growth
EPS Next Y64.11%
EPS Next 2Y26.62%
EPS Next 3Y16.1%
EPS Next 5Y8.25%
Revenue Next Year-49.69%
Revenue Next 2Y-31.17%
Revenue Next 3Y-19.74%
Revenue Next 5Y24.44%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ACRS Yearly Revenue VS EstimatesACRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ACRS Yearly EPS VS EstimatesACRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRS Price Earnings VS Forward Price EarningsACRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRS Per share dataACRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ACRS's earnings are expected to grow with 16.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.62%
EPS Next 3Y16.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACLARIS THERAPEUTICS INC

NASDAQ:ACRS (12/5/2025, 8:01:59 PM)

After market: 2.92 0 (0%)

2.92

-0.09 (-2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners80.48%
Inst Owner Change-6.59%
Ins Owners2.58%
Ins Owner Change0.46%
Market Cap316.38M
Revenue(TTM)15.74M
Net Income(TTM)-141.68M
Analysts84.62
Price Target7.82 (167.81%)
Short Float %3.7%
Short Ratio3.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.46%
Min EPS beat(2)4.07%
Max EPS beat(2)12.85%
EPS beat(4)2
Avg EPS beat(4)-84.06%
Min EPS beat(4)-353.03%
Max EPS beat(4)12.85%
EPS beat(8)5
Avg EPS beat(8)-248.11%
EPS beat(12)9
Avg EPS beat(12)-161.66%
EPS beat(16)13
Avg EPS beat(16)-117.11%
Revenue beat(2)2
Avg Revenue beat(2)78.57%
Min Revenue beat(2)26.93%
Max Revenue beat(2)130.22%
Revenue beat(4)4
Avg Revenue beat(4)124.24%
Min Revenue beat(4)11.41%
Max Revenue beat(4)328.42%
Revenue beat(8)7
Avg Revenue beat(8)123.77%
Revenue beat(12)10
Avg Revenue beat(12)148.98%
Revenue beat(16)11
Avg Revenue beat(16)175.64%
PT rev (1m)1.82%
PT rev (3m)1.82%
EPS NQ rev (1m)-4.76%
EPS NQ rev (3m)-8.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.16%
Revenue NQ rev (1m)48.92%
Revenue NQ rev (3m)40.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.1
P/FCF N/A
P/OCF N/A
P/B 2.63
P/tB 2.63
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.15
BVpS1.11
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -80.71%
ROE -117.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.98%
FCFM N/A
ROA(3y)-46.3%
ROA(5y)-49.43%
ROE(3y)-61.73%
ROE(5y)-73.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.2%
GM growth 5Y35.7%
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7420.2%
Cap/Sales 233.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.92
Quick Ratio 3.92
Altman-Z -4.68
F-Score2
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)1560.12%
Cap/Depr(5y)949.63%
Cap/Sales(3y)66.06%
Cap/Sales(5y)41.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-165.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y64.11%
EPS Next 2Y26.62%
EPS Next 3Y16.1%
EPS Next 5Y8.25%
Revenue 1Y (TTM)-41.87%
Revenue growth 3Y40.43%
Revenue growth 5Y34.65%
Sales Q2Q%-24.09%
Revenue Next Year-49.69%
Revenue Next 2Y-31.17%
Revenue Next 3Y-19.74%
Revenue Next 5Y24.44%
EBIT growth 1Y-67.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.67%
OCF growth 3YN/A
OCF growth 5YN/A

ACLARIS THERAPEUTICS INC / ACRS FAQ

What is the fundamental rating for ACRS stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACRS.


Can you provide the valuation status for ACLARIS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ACLARIS THERAPEUTICS INC (ACRS). This can be considered as Overvalued.


Can you provide the profitability details for ACLARIS THERAPEUTICS INC?

ACLARIS THERAPEUTICS INC (ACRS) has a profitability rating of 1 / 10.


Can you provide the financial health for ACRS stock?

The financial health rating of ACLARIS THERAPEUTICS INC (ACRS) is 6 / 10.


Can you provide the expected EPS growth for ACRS stock?

The Earnings per Share (EPS) of ACLARIS THERAPEUTICS INC (ACRS) is expected to grow by 64.11% in the next year.